Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
Open Access
- 17 January 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (3) , 1557-1565
Abstract
Antibody–drug conjugates (ADCs) are the spearhead of targeted therapies. According to the technology used, the conjugation of a cytotoxic drug to an antibody can produce suboptimal heterogeneous species, impacting the overall efficacy. Herein, we describe the synthesis of HER2-targeting ADCs with three disulfide rebridging heads, allowing homogeneous and site-specific bioconjugation: dibromomaleimide (DBM), dithiomaleimide (DTM), and hybrid thio-bromomaleimide (TBM) chemical bricks to combine the properties of both previously used heads. The primary purpose of this study was to compare the reactivity of these three chemical bricks in the bioconjugation process. Then, the resulting ADCs were evaluated in terms of physicochemical stability, binding, and biological activity. We have demonstrated that the higher percentage of a drug-to-antibody ratio of 4 was obtained with TBM. Additionally, the reaction time was drastically reduced with TBM in comparison to DTM. The three ADCs showed good binding to HER2 and in vitro cytotoxicity, which validate the TBM structure as an attractive alternative scaffold for rebridging bioconjugation.Keywords
Funding Information
- Association Nationale de la Recherche et de la Technologie (2017/0516)
- Conseil Régional du Centre-Val de Loire (ARD2020-Biom?dicaments)
This publication has 22 references indexed in Scilit:
- In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody RatiosMolecular Pharmaceutics, 2015
- Next generation maleimides enable the controlled assembly of antibody–drug conjugatesvianative disulfide bond bridgingOrganic & Biomolecular Chemistry, 2014
- Bridging Disulfides for Stable and Defined Antibody Drug ConjugatesBioconjugate Chemistry, 2014
- Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug ConjugatesBioconjugate Chemistry, 2014
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences, 2012
- Site-specific chemical protein conjugation using genetically encoded aldehyde tagsNature Protocols, 2012
- In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylationBioconjugate Chemistry, 2011
- An engineered selenocysteine defines a unique class of antibody derivativesProceedings of the National Academy of Sciences, 2008
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateClinical Cancer Research, 2004